Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
Blueprint Medicines Corporation (NASDAQ: BPMC) will hold a live conference call and webcast on April 12, 2021, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Blueprint Medicines Corporation (NASDAQ: BPMC) will hold a live conference call and webcast on April 12, 2021, at 8:00 a.m. ET. The event will review new data from its portfolio in precision oncology and hematology, which will also be showcased at the AACR Annual Meeting 2021 from April 9-14, 2021. Interested parties can join the call by dialing (855) 728-4793 (domestic) or (503) 343-6666 (international) using conference ID 5548976. An archived webcast will be available on their website for 30 days post-event.
Details
News Market Reaction – BPMC
The recorded move for BPMC in the trading session of this news was +1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 12, 2021 to review new data for multiple research- and clinical-stage programs across its precision oncology and hematology portfolio. The data will also be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 9-14, 2021.
Conference Call Information
To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 5548976. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-host-virtual-investor-event-and-webcast-to-review-new-data-presented-at-aacr-annual-meeting-on-monday-april-12-2021-301261789.html
SOURCE Blueprint Medicines Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.